Table 1

 Baseline characteristics by treatment group

VariableMP (n = 15)IFX (n = 12)
Values are median (range), except when expressed as percentages.
DMARDs, disease modifying antirheumatic drugs; VAS, visual analogue scale.
The differences between the two treatment groups were not statistically significant.
Female/male (%)73/27100/0
Age (years)56 (35–79)48 (34–60)
Disease duration (years)12 (1–24)10 (2–20)
Rheumatoid factor positivity (%)8767
Previous DMARDs (n)3 (1–7)3 (2–6)
Swollen joint count (n)22 (7–38)16 (8–27)
Tender joint count (n)24 (7–38)20 (6–44)
Serum CRP (g/l)19 (3–63)13 (3–43)
Patient’s assessment of pain (VAS, 100 mm)64 (18–100)50 (15–80)
Patient’s assessment of fatigue (VAS, 100 mm)60 (13–100)56 (14–97)
Patient’s global assessment of disease activity (VAS, 100 mm)63 (19–100)52 (15–80)
Physician’s global assessment of disease activity (VAS, 100 mm)58 (18–83)43 (14–85)
Health Activity Questionnaire (score)1.5 (0.75–2.13)1.3 (0.75–2)
Morning stiffness (min)114 (30–420)76 (30–150)
Prednisolone dose (mg/day)5 (0–7.5)5 (0–7.5)
Methotrexate dose (mg/week)12.5 (10–15)15 (10–15)